Recipharm Opens Analytical Lab in India

CDMO Recipharm opened a new lab in Bengaluru, India, to expand its analytical testing capabilities for nitrosamines, extractables and leachables, and elemental impurity testing. The 5,000-ft2 lab is cGMP/cGLP compliant and designed to support biotech and pharma customers in their R&D of oral solids, drug delivery, inhalation, vaccines, and injectables.

“With new testing capabilities, Recipharm now provides customers with accurate and reliable testing services, method development and validation, and batch release testing of excipients, drug substance, drug product, and container closure systems,” according to Gregor Kawaletz, head of oral solid dosages business unit. “The launch of Recipharm’s new analytical lab marks a new era in cutting-edge laboratory techniques for us as a group.”

The lab is fully operational and employs 30 new and experienced research scientists, he added.

Previous articleCan a Caterpillar Transform the Future of Drug Delivery?
Next articleEffective IoT Infrastructure Critical for Digital Drug Firms